Cannabis Herbal Formula Matches Lorazepam for Insomnia in Clinical Trial

A groundbreaking Phase II clinical trial has found that a traditional cannabis-based herbal formula performed just as well as lorazepam — one of the most commonly prescribed sleep medications in the world — for treating chronic insomnia. The study, published in the Journal of Cannabis Research in February 2026, adds to a growing body of evidence that cannabis-derived treatments could offer meaningful alternatives to benzodiazepines for the estimated 50 to 70 million Americans who struggle with sleep disorders.

The findings are particularly significant because benzodiazepines like lorazepam, while effective for short-term sleep relief, carry well-documented risks of dependence, cognitive impairment, and dangerous withdrawal symptoms. A plant-based alternative that delivers comparable results with a cleaner safety profile could reshape how clinicians approach one of the most pervasive health complaints in modern medicine.

Key Takeaways

• The study was published in the Journal of Cannabis Research in February 2026, conducted by researchers from Thai universities.
• A Phase II clinical trial found a cannabis-based herbal formula matched lorazepam (0.5 mg) for treating chronic insomnia over four weeks.
• Both groups achieved PSQI scores below the clinical insomnia threshold, with the cannabis group scoring 3.44 vs. lorazepam's 4.78.

Table of Contents

• Inside the Study: Design and Methodology
• The Results: Cannabis Formula Outperformed Expectations
• The Formula: Traditional Thai Anti-Pom-Leung Fever Medicine
• Safety: No Clinically Significant Side Effects
• What This Means for Insomnia Treatment
• The Bigger Picture: Cannabis as Medicine in 2026

Inside the Study: Design and Methodology

The trial was conducted at Prapokklao Hospital in Thailand and led by researchers from Suan Sunandha Rajabhat University and Mahidol University. It used a randomized, double-blind, active-controlled non-inferiority design — the gold standard for determining whether a new treatment works at least as well as an established one.

One hundred participants with diagnosed chronic insomnia were enrolled and randomly assigned to one of two groups: one received the cannabis-based herbal formulation, and the other received lorazepam at a standard dose of 0.5 milligrams. The treatment period lasted four weeks, with sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI), a widely validated tool used in sleep research worldwide.

Of the 100 participants enrolled, 82 completed the full trial — 41 in each group. The dropout rate was comparable between groups and not attributed to adverse effects, a positive indicator for both treatment arms.

The Results: Cannabis Formula Outperformed Expectations

The results exceeded what many researchers anticipated. By week four, participants in the cannabis herbal formula group had an average PSQI score of 3.44, while the lorazepam group scored 4.78. Both results fell below the clinical threshold of 5 — the cutoff below which insomnia is generally considered resolved — meaning both treatments effectively addressed chronic insomnia in the majority of participants.

The difference between the two scores was -1.34, which met the study's pre-defined non-inferiority criteria. In practical terms, the cannabis-based formula didn't just match lorazepam — it produced numerically better sleep quality scores, though the researchers cautioned that the difference was not statistically significant enough to claim superiority.

Quality of life and stress measures also improved in both treatment groups, suggesting that better sleep cascaded into broader wellness improvements. Participants reported feeling more rested, less anxious during the day, and more capable of handling daily responsibilities.

The Formula: Traditional Thai Anti-Pom-Leung Fever Medicine

The cannabis-based treatment used in the trial was not a simple CBD oil or THC capsule. It was a traditional Thai multi-herbal remedy known as Anti-Pom-Leung Fever medicine, which combines cannabis with other botanicals used in Thai traditional medicine for centuries.

While the full ingredient breakdown has not been publicly disclosed in detail, the formulation represents a holistic approach that leverages the entourage effect [Quick Definition: The theory that cannabis compounds work better together than isolated] — the theory that cannabis compounds work more effectively in combination with other plant molecules than in isolation. This is consistent with a broader trend in cannabis research away from isolated cannabinoids and toward full-spectrum [Quick Definition: A product containing all naturally occurring cannabinoids, terpenes, and plant compounds] or multi-botanical formulations.

Thailand has been at the forefront of integrating traditional cannabis medicine into modern healthcare. The country decriminalized cannabis in 2022 and has since invested heavily in research exploring the therapeutic potential of traditional formulations that have been used in Thai medicine for generations.

Safety: No Clinically Significant Side Effects

Perhaps the most compelling aspect of the trial was the safety data. No clinically significant adverse effects were reported in either group. Laboratory assessments — including liver enzymes, kidney function, cholesterol, blood sugar, and heart rhythm readings — showed no meaningful differences between the cannabis formula group and the lorazepam group.

This stands in stark contrast to the well-documented side effect profile of benzodiazepines, which can include next-day drowsiness, memory impairment, loss of coordination, and — with prolonged use — physical dependence and potentially life-threatening withdrawal symptoms. The American Geriatric Society has specifically flagged benzodiazepines as inappropriate for older adults due to fall risk and cognitive effects, yet they remain widely prescribed.

A cannabis-based alternative that offers comparable efficacy without these risks could be particularly valuable for older patients, who represent both the fastest-growing demographic of cannabis users and the population most vulnerable to benzodiazepine side effects.

What This Means for Insomnia Treatment

The trial's implications extend beyond the specific herbal formula tested. It adds to a mounting evidence base that cannabis-derived treatments can play a legitimate role in sleep medicine — not as a last resort, but as a frontline option.

Previous research has already established that certain cannabinoids, particularly CBN and CBD, have sedative properties. A 2025 study found that CBN products were associated with improved sleep onset and duration in adults with insomnia. And the broader landscape of 70-plus cannabis studies published in 2026 includes multiple findings related to sleep improvement across different populations.

The challenge has always been moving from anecdotal evidence and observational studies to the kind of rigorous, controlled clinical trials that can change clinical practice. The Thailand trial represents exactly that kind of evidence. Its randomized, double-blind design and active comparator arm give the results credibility that earlier cannabis-sleep studies lacked.

However, significant hurdles remain before cannabis-based insomnia treatments can be widely recommended. Regulatory approval processes in the United States and Europe require larger, multi-site trials. The specific formulation used in this study is rooted in Thai traditional medicine and may not be directly translatable to other healthcare systems.

And the ongoing federal classification of cannabis in the U.S. creates barriers to the kind of large-scale research needed.

The Bigger Picture: Cannabis as Medicine in 2026

This trial arrives at a moment when the relationship between cannabis and mainstream medicine is rapidly evolving. Over 70 cannabis-related studies published in 2026 alone have explored applications ranging from cancer treatment and chronic pain to brain injury recovery and metabolic disorders.

With federal rescheduling from Schedule I to Schedule III [Quick Definition: A mid-level federal drug classification including ketamine and testosterone] on the horizon in the United States, researchers anticipate that barriers to clinical trials will ease significantly. That could open the floodgates for studies testing cannabis formulations against established pharmaceuticals for conditions like insomnia, anxiety, chronic pain, and epilepsy.

For the millions of insomnia sufferers currently weighing the risks and benefits of pharmaceutical sleep aids, the Thailand trial offers something valuable: credible, controlled evidence that cannabis-based alternatives deserve serious consideration.

---

Pull-Quote Suggestions:

"The study, published in the Journal of Cannabis Research in February 2026, adds to a growing body of evidence that cannabis-derived treatments could offer meaningful alternatives to benzodiazepines for the estimated 50 to 70 million Americans who struggle with sleep disorders."

"For the millions of insomnia sufferers currently weighing the risks and benefits of pharmaceutical sleep aids, the Thailand trial offers something valuable: credible, controlled evidence that cannabis-based alternatives deserve serious consideration."

"The trial was conducted at Prapokklao Hospital in Thailand and led by researchers from Suan Sunandha Rajabhat University and Mahidol University."

---

Why It Matters: A Phase II clinical trial found a cannabis-based herbal formula worked as well as lorazepam for chronic insomnia with no adverse effects. Here's what it means.